Compass Pathways vs ATAI Life Sciences BV: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Compass Pathways Plc (CMPS)

ATAI Life Sciences BV (ATAI)

Q3 202615 Jul – 28 Sep 2026

▲2▼2

ATAI Surges on Lilly Buyout, But Legal and Valuation Risks Loom

Eli Lilly's Acquisition of AtaiBeckley Eli Lilly agreed to buy subsidiary AtaiBeckley for up to $3.8B, sending ATAI shares up over 30% to a four-year high. The deal validates ATAI's pipeline and provides cash plus milestone payments.
This was the primary catalyst for the stock's strong performance in Q3.
Positive Clinical and Analyst Developments Positive Phase 2b results for VLS-01 and a Canaccord upgrade to $17, along with Russell 2000/3000 inclusion, added support to the stock price during the quarter.
These events contributed to the positive momentum and investor confidence.
Legal Probes into Deal Fairness Two law firms are investigating whether AtaiBeckley sold too cheaply compared to analyst targets of $14–$25, creating legal uncertainty that could affect the deal's completion or terms.
This is a new risk that emerged during the period and could weigh on the stock.
Stretched Valuation and Financial Losses ATAI traded above Lilly's cash offer at 13.2x book value despite $663M losses on $3.5M revenue, raising concerns about sustainability and potential downside if the deal fails.
This highlights the underlying financial weakness and valuation risk that could reverse gains.

August 202616 Jul – 28 Sep 2026

▲2▼1

Lilly completes AtaiBeckley buyout; deal value and fairness questioned

Lilly completes AtaiBeckley acquisition Eli Lilly closed its purchase of AtaiBeckley, ATAI's subsidiary, after shareholders approved it. This locks in the $6.75 per share cash payout plus possible milestone payments, giving ATAI investors a definite exit and removing deal-failure risk.
This is the final, most important event that determines ATAI's value for shareholders.
Law firm probes fairness of sale price Wohl & Fruchter is investigating whether AtaiBeckley's board sold too cheaply. The total potential price of $9.25 per share is far below analyst targets of $14 to $25, so the probe raises the chance of a higher bid or legal challenge, but also uncertainty.
It highlights a real counterweight: the deal may undervalue ATAI, which could affect the final price or create delays.
Lilly signals more deals, validates ATAI asset Lilly's CEO said the company will keep making larger acquisitions in areas like psychiatry, citing the AtaiBeckley deal as an example. This shows Lilly's strong commitment to the asset, which supports the value of the contingent milestone payments ATAI shareholders may receive.
It confirms strategic buyer interest and increases confidence that the milestone payments will be pursued.
Brodsky & Smith investigates merger process Another law firm, Brodsky & Smith, is looking into whether AtaiBeckley's board ran a fair sale process. This adds legal scrutiny but is similar to other investigations and does not change the deal terms yet.
It is a new legal development that could pressure the deal, though its impact is uncertain.

Latest16 Jul – 28 Sep 2026

▲2▼1

Lilly completes AtaiBeckley buyout; deal value and fairness questioned

Lilly completes AtaiBeckley acquisition Eli Lilly closed its purchase of AtaiBeckley, ATAI's subsidiary, after shareholders approved it. This locks in the $6.75 per share cash payout plus possible milestone payments, giving ATAI investors a definite exit and removing deal-failure risk.
This is the final, most important event that determines ATAI's value for shareholders.
Law firm probes fairness of sale price Wohl & Fruchter is investigating whether AtaiBeckley's board sold too cheaply. The total potential price of $9.25 per share is far below analyst targets of $14 to $25, so the probe raises the chance of a higher bid or legal challenge, but also uncertainty.
It highlights a real counterweight: the deal may undervalue ATAI, which could affect the final price or create delays.
Lilly signals more deals, validates ATAI asset Lilly's CEO said the company will keep making larger acquisitions in areas like psychiatry, citing the AtaiBeckley deal as an example. This shows Lilly's strong commitment to the asset, which supports the value of the contingent milestone payments ATAI shareholders may receive.
It confirms strategic buyer interest and increases confidence that the milestone payments will be pursued.
Brodsky & Smith investigates merger process Another law firm, Brodsky & Smith, is looking into whether AtaiBeckley's board ran a fair sale process. This adds legal scrutiny but is similar to other investigations and does not change the deal terms yet.
It is a new legal development that could pressure the deal, though its impact is uncertain.

July 202615 Jul – 17 Jul 2026

▲3

Eli Lilly to buy AtaiBeckley for up to $3.8B, stock soars

Eli Lilly acquisition Eli Lilly agreed to buy AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in milestone payments, valuing the deal at up to $3.8 billion. The stock jumped over 30% to a four-year high, as the buyout locks in a premium and validates the psychedelic medicine sector.
This is the single biggest driver of ATAI's price this period, directly setting a cash floor and re-rating the stock.
Pipeline milestone and analyst upgrade AtaiBeckley completed dosing in the Phase 2b trial of VLS-01 for treatment-resistant depression, with results due in late 2026. Canaccord raised its price target to $17, citing the trial staying on track. This progress supports the company's value and the milestone payments tied to the deal.
It shows the clinical progress that underpins the acquisition's contingent value and future payments.
Index inclusion AtaiBeckley was added to the Russell 2000 and Russell 3000 indices, which can bring in passive fund buying. While the acquisition news dominates, index inclusion adds a steady source of demand for the shares.
It is a separate positive event that increases demand for the stock, though its impact is smaller than the buyout.
Valuation and profitability concerns After the surge, AtaiBeckley trades at 13.2 times book value, far above industry averages, and the company lost $663 million on just $3.5 million of revenue. The market is pricing in huge future potential, but the stock now trades above Lilly's cash offer, leaving little upside if milestones fail.
It provides a fair counterweight: the deal caps near-term gains and the rich valuation could unwind if the acquisition or milestones disappoint.

15 Jul – 17 Jul 2026

▲3

Eli Lilly to buy AtaiBeckley for up to $3.8B, stock soars

Eli Lilly acquisition Eli Lilly agreed to buy AtaiBeckley for $6.75 per share in cash plus up to $2.50 per share in milestone payments, valuing the deal at up to $3.8 billion. The stock jumped over 30% to a four-year high, as the buyout locks in a premium and validates the psychedelic medicine sector.
This is the single biggest driver of ATAI's price this period, directly setting a cash floor and re-rating the stock.
Pipeline milestone and analyst upgrade AtaiBeckley completed dosing in the Phase 2b trial of VLS-01 for treatment-resistant depression, with results due in late 2026. Canaccord raised its price target to $17, citing the trial staying on track. This progress supports the company's value and the milestone payments tied to the deal.
It shows the clinical progress that underpins the acquisition's contingent value and future payments.
Index inclusion AtaiBeckley was added to the Russell 2000 and Russell 3000 indices, which can bring in passive fund buying. While the acquisition news dominates, index inclusion adds a steady source of demand for the shares.
It is a separate positive event that increases demand for the stock, though its impact is smaller than the buyout.
Valuation and profitability concerns After the surge, AtaiBeckley trades at 13.2 times book value, far above industry averages, and the company lost $663 million on just $3.5 million of revenue. The market is pricing in huge future potential, but the stock now trades above Lilly's cash offer, leaving little upside if milestones fail.
It provides a fair counterweight: the deal caps near-term gains and the rich valuation could unwind if the acquisition or milestones disappoint.